SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (464)6/24/2004 12:04:18 PM
From: Biomaven  Read Replies (2) | Respond to of 933
 
A repeat of a post I made on the Valuation thread in response to a question about why prostate would be OK given the problems in the colorectal trial:

The way they describe the problem - "cumulative drug toxicities in patients who had been previously treated with oxaliplatin" - leads me to believe that it was a problem with sensory neuropathy. Cumulative sensory neuropathy is the limiting toxicity of oxaliplatin by itself, and my guess is that epo simply added to this.

If this is correct, it doesn't impact the issue of using epo in patients that haven't been heavily pre-treated with oxaliplatin.

Peter



To: Biomaven who wrote (464)6/26/2004 8:48:18 AM
From: tom pope  Respond to of 933
 
I did send a mildly worded rocket to the SEC, not because a lot of money is involved but because the pattern of a 50% haircut followed by some recovery after the news is out raises suspicions, in my mind at least, that should be followed up.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News